BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

Core Viewpoint - BrainsWay has entered into a strategic equity financing agreement with BrainStim Health Inc. to enhance access to mental health care through investments in innovative clinical service platforms [1][2] Group 1: Investment Details - BrainsWay will initially invest $1.0 million in BrainStim, with the potential for an additional $1.5 million based on milestones, acquiring a minority position through preferred, annually compounding securities [1] - This investment marks BrainsWay's fifth minority-stake investment in growth-oriented clinical service platforms, aligning with its strategic initiative to expand access to advanced mental health interventions [2] Group 2: Company Background - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [4] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and is committed to advancing its clinical applications [4] Group 3: BrainStim Overview - BrainStim focuses on delivering effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression, particularly for veterans and first responders [5] - The practice employs a team of board-certified psychiatrists and advanced psychiatric nurse practitioners to provide cutting-edge treatment options [5]